Malignant melanoma as a target malignancy for the study of the anti-metastatic properties of the heparins

Cancer and Metastasis Reviews

Volumn 29, Issue 4, 2010, Pages 777-784

  Maraveyas, Anthony ^a,b   Johnson, Miriam J ^c   Xiao, Yu Pei ^a   Noble, Simon ^d  

^a UNIVERSITY OF HULL   (United Kingdom)

^b CASTLE HILL HOSPITAL   (United Kingdom)

^c St Catherine's Hospice Scarborough   (United Kingdom)

^d CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Anti metastatic; Low molecular weight heparins; Metastatic melanoma; Selectin

Indexed keywords

ANTINEOPLASTIC AGENT; DACARBAZINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENOXAPARIN; FONDAPARINUX; FOTEMUSTINE; HEPARIN; HEPARIN DERIVATIVE; NADROPARIN; PADGEM PROTEIN; PROTEINASE ACTIVATED RECEPTOR 1; TEMOZOLOMIDE; THROMBIN; THROMBOPLASTIN; TINZAPARIN; TRANSCRIPTION FACTOR AP 2;

BLOOD BRAIN BARRIER; BLOOD CLOTTING; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; HUMAN; IN VITRO STUDY; LUNG SMALL CELL CANCER; MELANOMA; MELANOMA B16; MELANOMA METASTASIS; METASTASIS INHIBITION; METASTASIS POTENTIAL; MOLECULAR DOCKING; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TUMOR PROMOTION; ANIMAL; METASTASIS; PATHOLOGY;

ANIMALS; HEPARIN; HUMANS; MELANOMA;

EID: 79952197605     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-010-9263-y     Document Type: Review

References (71)

1. Sgouros, J., & Maraveyas, A. (2008). Excess premature (3-month) mortality in advanced pancreatic cancer could be related to fatal vascular thromboembolic events. A hypothesis based on a systematic review of phase III chemotherapy studies in advanced pancreatic cancer. Acta Oncológica, 47(3), 337-346. (Pubitemid 351414919)
2. Chew, H. K., Wun, T., Harvey, D., Zhou, H., & White, R. H. (2006). Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Archives of Internal Medicine, 166(4), 458-464.
3. Altinbas, M., Coskun, H. S., Er, O., Ozkan, M., Eser, B., Unal, A., et al. (2004). A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. Journal of Thrombosis and Haemostasis, 2 (8), 1266-1271. (Pubitemid 40186120)
4. Slotman, B., Faivre-Finn, C., Kramer, G., Rankin, E., Snee, M., Hatton, M., et al. (2007). Prophylactic cranial irradiation in extensive small-cell lung cancer. The New England Journal of Medicine, 357(7), 664-672. (Pubitemid 47267236)
5. Douglas, J. G., & Margolin, K. (2002). The treatment of brain metastases from malignant melanoma. Seminars in Oncology, 29 (5), 518-524. (Pubitemid 35178291)
6. Wen, P. Y., Black, P. M., & Joeffler, S. L. (2001). Treatment of metastatic cancer. In V. T. Devita, S. Hellman, & S. A. Rosenberg (Eds.), Cancer: principles and practice of oncology (6th ed., pp. 2655-2670). Philadelphia: Lippincott, Williams & Wilkins.
7. Barnholtz-Sloan, J. S., Sloan, A. E., Davis, F. G., Vigneau, F. D., Lai, P., & Sawaya, R. E. (2004). Incidence proportions of brain metastases in patients diagnosed (1973-2001) in the Metropolitan Detroit Cancer Surveillance System. Journal of Clinical Oncology, 22(14), 2865-2872. (Pubitemid 41079905)
8. Amer, M. H., Al-Sarraf, M., Baker, L. H., & Vaitkevicius, V. K. (1978). Malignant melanoma and central nervous system metas-tases: incidence, diagnosis, treatment and survival. Cancer, 42(2), 660-668. (Pubitemid 8405861)
9. Budman, D. R., Camacho, E., & Wittes, R. E. (1978). The current causes of death in patients with malignant melanoma. European Journal of Cancer, 14(4), 327-330. (Pubitemid 8310441)
10. Bullard, D. E., Cox, E. B., & Seigler, H. F. (1981). Central nervous system metastases in malignant melanoma. Neurosurgery, 8(1), 26-30. (Pubitemid 11146127)
11. Patel, J. K., Didolkar, M. S., Pickren, J. W., & Moore, R. H. (1978). Metastatic pattern of malignant melanoma. A study of 216 autopsy cases. American Journal of Surgery, 135(6), 807-810. (Pubitemid 8377329)
12. Avril, M. F., Aamdal, S., Grob, J. J., Hauschild, A., Mohr, P., Bonerandi, J. J., et al. (2004). Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. Journal of Clinical Oncology, 22(6), 1118-1125. (Pubitemid 41095046)
13. Middleton, M. R., Grob, J. J., Aaronson, N., Fierlbeck, G., Tilgen, W., Seiter, S., et al. (2000). Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. Journal of Clinical Oncology, 18(1), 158-166. (Pubitemid 30036349)
14. Partridge, M. A., & Marcantonio, E. E. (2006). Initiation of attachment and generation of mature focal adhesions by integrincontaining filopodia in cell spreading. Molecular Biology of the Cell, 17(10), 4237-4248. (Pubitemid 44522045)
15. Fidler, I. J. (1970). Metastasis: quantitative analysis of distribution and fate of tumor emboli labeled with 125i-5-iodo-2'- deoxyuridine. Journal of the National Cancer Institute, 45(4), 773-782.
16. Bromberg, M. E., Konigsberg, W. H., Madison, J. F., Pawashe, A., & Garen, A. (1995). Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation. Proceedings of the National Academy of Sciences of the United States of America, 92(18), 8205-8209.
17. Honn, K. V., Tang, D. G., & Crissman, J. D. (1992). Platelets and cancer metastasis: a causal relationship? Cancer and Metastasis Reviews, 11(3-4), 325-351.
18. Gasic, G. J. (1984). Role of plasma, platelets, and endothelial cells in tumor metastasis. Cancer and Metastasis Reviews, 3(2), 99-114.
19. Karpatkin, S., & Pearlstein, E. (1981). Role of platelets in tumor cell metastases. Annals of Internal Medicine, 95(5), 636-641. (Pubitemid 12231807)
20. Palumbo, J. S., Talmage, K. E., Massari, J. V., La Jeunesse, C. M., Flick, M. J., Kombrinck, K. W., et al. (2005). Platelets and fibrin (ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood, 105(1), 178-185. (Pubitemid 40053080)
21. Nash, G. F., Turner, L. F., Scully, M. F., & Kakkar, A. K. (2002). Platelets and cancer. The Lancet Oncology, 3(7), 425-430. (Pubitemid 36958273)
22. Jurasz, P., Alonso-Escolano, D., & Radomski, M. W. (2004). Platelet-cancer interactions: mechanisms and pharmacology of tumour cell-induced platelet aggregation. British Journal of Pharmacology, 143(7), 819-826. (Pubitemid 39664840)
23. Nieswandt, B., Hafner, M., Echtenacher, B., & Mannel, D. N. (1999). Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Research, 59(6), 1295-1300. (Pubitemid 29136261)
24. Varon, D., & Brill, A. (2001). Platelets cross-talk with tumor cells. Haemostasis, 31(Suppl 1), 64-66.
25. Baj-Krzyworzeka, M., Majka, M., Pratico, D., Ratajczak, J., Vilaire, G., Kijowski, J., et al. (2002). Platelet-derived microparticles stimulate proliferation, survival, adhesion, and chemotaxis of hematopoietic cells. Experimental Hematology, 30(5), 450-459. (Pubitemid 34556736)
26. Varki, N. M., & Varki, A. (2002). Heparin inhibition of selectinmediated interactions during the hematogenous phase of carcinoma metastasis: rationale for clinical studies in humans. Seminars in Thrombosis and Hemostasis, 28(1), 53-66. (Pubitemid 34194873)
27. Browder, T., Folkman, J., & Pirie-Shepherd, S. (2000). The hemostatic system as a regulator of angiogenesis. The Journal of Biological Chemistry, 275(3), 1521-1524. (Pubitemid 30060762)
28. Fischer, E. G., Ruf, W., & Mueller, B. M. (1995). Tissue factorinitiated thrombin generation activates the signaling thrombin receptor on malignant melanoma cells. Cancer Research, 55(8), 1629-1632.
29. Melnikova, V. O., Villares, G. J., & Bar-Eli, M. (2008). Emerging roles of PAR-1 and PAFR in melanoma metastasis. Cancer Microenvironment, 1(1), 103-111.
30. Tellez, C., & Bar-Eli, M. (2003). Role and regulation of the thrombin receptor (PAR-1) in human melanoma. Oncogene, 22 (20), 3130-3137. (Pubitemid 36713765)
31. Mueller, B. M., Reisfeld, R. A., Edgington, T. S., & Ruf, W. (1992). Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proceedings of the National Academy of Sciences of the United States of America, 89(24), 11832-11836. (Pubitemid 23004738)
32. Shi, X., Gangadharan, B., Brass, L. F., Ruf, W., & Mueller, B. M. (2004). Protease-activated receptors (PAR1 and PAR2) contribute to tumor cell motility and metastasis. Molecular Cancer Research, 2(7), 395-402. (Pubitemid 39031073)
33. Bromberg,M. E., Bailly,M.A.,&Konigsberg,W. H. (2001). Role of protease-activated receptor 1 in tumor metastasis promoted by tissue factor. Thrombosis and Haemostasis, 86(5), 1210-1214. (Pubitemid 33064570)
34. Bar-Eli, M. (1999). Role of AP-2 in tumor growth and metastasis of humanmelanoma. Cancer and Metastasis Reviews, 18(3), 377-385. (Pubitemid 30104070)
35. Silini, A., Ghilardi, C., Ardinghi, C., Bernasconi, S., Oliva, P., Carraro, F., et al. (2010). Protease-activated receptor-1 (PAR-1) promotes the motility of human melanomas and is associated to their metastatic phenotype. Clinical & Experimental Metastasis, 27(1), 43-53.
36. Massi, D., Naldini, A., Ardinghi, C., Carraro, F., Franchi, A., Paglierani, M., et al. (2005). Expression of protease-activated receptors 1 and 2 in melanocytic nevi and malignant melanoma. Human Pathology, 36(6), 676-685. (Pubitemid 40922575)
37. Villares, G. J., Zigler, M., Wang, H., Melnikova, V. O., Wu, H., Friedman, R., et al. (2008). Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. Cancer Research, 68(21), 9078-9086.
38. Melnikova, V. O., & Bar-Eli, M. (2009). Inflammation and melanoma metastasis. Pigment Cell & Melanoma Research, 22 (3), 257-267.
39. Borsig, L., Wong, R., Feramisco, J., Nadeau, D. R., Varki, N. M., & Varki, A. (2001). Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proceedings of the National Academy of Sciences of the United States of America, 98(6), 3352-3357. (Pubitemid 32220849)
40. Koop, S., MacDonald, I. C., Luzzi, K., Schmidt, E. E., Morris, V. L., Grattan, M., et al. (1995). Fate of melanoma cells entering the microcirculation: over 80% survive and extravasate. Cancer Research, 55(12), 2520-2523.
41. Weiss, L. (1994). Inefficiency of metastasis from colorectal carcinomas. Relationship to local therapy for hepatic metastasis. Cancer Treatment and Research, 69, 1-11.
42. Stevenson, J. L., Choi, S. H., & Varki, A. (2005). Differential metastasis inhibition by clinically relevant levels of heparins- correlation with selectin inhibition, not antithrombotic activity. Clinical Cancer Research, 11(19 Pt 1), 7003-7011. (Pubitemid 41428760)
43. Koenig, A., Norgard-Sumnicht, K., Linhardt, R., & Varki, A. (1998). Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. Journal of Clinical Investigation, 101(4), 877-889. (Pubitemid 28096085)
44. Stevenson, J. L., Varki, A., & Borsig, L. (2007). Heparin attenuates metastasis mainly due to inhibition of P- and Lselectin, but non-anticoagulant heparins can have additional effects. Thrombosis Research, 120(Suppl 2), S107-S111. (Pubitemid 350101778)
45. Ramsay, A. G., Marshall, J. F., & Hart, I. R. (2007). Integrin trafficking and its role in cancer metastasis. Cancer and Metastasis Reviews, 26(3-4), 567-578. (Pubitemid 350115108)
46. Fritzsche, J., Simonis, D., & Bendas, G. (2008). Melanoma cell adhesion can be blocked by heparin in vitro: suggestion of VLA-4 as a novel target for antimetastatic approaches. Thrombosis and Haemostasis, 100(6), 1166-1175.
47. Zhang, C., Liu, Y., Gao, Y., Shen, J., Zheng, S., Wei, M., et al. (2009). Modified heparins inhibit integrin alpha(IIb)beta(3) mediated adhesion of melanoma cells to platelets in vitro and in vivo. International Journal of Cancer, 125(9), 2058-2065.
48. Lydolph, M. C., Morgan-Fisher, M., Hoye, A. M., Couchman, J. R., Wewer, U. M., & Yoneda, A. (2009). Alpha9beta1 integrin in melanoma cells can signal different adhesion states for migration and anchorage. Experimental Cell Research, 315(19), 3312-3324.
49. Witz, I. P. (2008). The selectin-selectin ligand axis in tumor progression. Cancer and Metastasis Reviews, 27(1), 19-30.
50. Fu, J., Naren, A. P., Gao, X., Ahmmed, G. U.,&Malik, A. B. (2005). Protease-activated receptor-1 activation of endothelial cells induces protein kinase Calpha-dependent phosphorylation of syntaxin 4 and Munc18c: Role in signaling p-selectin expression. The Journal of Biological Chemistry, 280(5), 3178-3184. (Pubitemid 40223779)
51. Kansas, G. S. (1996). Selectins and their ligands: current concepts and controversies. Blood, 88(9), 3259-3287. (Pubitemid 26365560)
52. Varki, A. (1997). Selectin ligands: will the real ones please stand up? Journal of Clinical Investigation, 99(2), 158-162. doi:10.1172/ JCI119142. (Pubitemid 27053457)
53. Kim, Y. J., Borsig, L., Varki, N. M., & Varki, A. (1998). P-selectin deficiency attenuates tumor growth and metastasis. Proceedings of the National Academy of Sciences of the United States of America, 95(16), 9325-9330. (Pubitemid 28506230)
54. Lee, D. Y., Park, K., Kim, S. K., Park, R. W., Kwon, I. C., Kim, S. Y., et al. (2008). Antimetastatic effect of an orally active heparin derivative on experimentally induced metastasis. Clinical Cancer Research, 14(9), 2841-2849.
55. Ludwig, R. J., Schon, M. P., & Boehncke, W. H. (2007). Pselectin: a common therapeutic target for cardiovascular disorders, inflammation and tumourmetastasis. Expert Opinion on Therapeutic Targets, 11(8), 1103-1117. (Pubitemid 47240681)
56. Ludwig, R. J., Alban, S., Bistrian, R., Boehncke, W. H., Kaufmann, R., Henschler, R., et al. (2006). The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on bloodborne metastasis in vivo. Thrombosis and Haemostasis, 95(3), 535-540.
57. Kim, Y. J., Borsig, L., Han, H. L., Varki, N. M., & Varki, A. (1999). Distinct selectin ligands on colon carcinoma mucins can mediate pathological interactions among platelets, leukocytes, and endothelium. The American Journal of Pathology, 155(2), 461-472. (Pubitemid 29370396)
58. Fuster, M. M., & Esko, J. D. (2005). The sweet and sour of cancer: glycans as novel therapeutic targets. Nature Reviews. Cancer, 5(7), 526-542. (Pubitemid 40942829)
59. Marshall, B. T., Long, M., Piper, J. W., Yago, T., McEver, R. P., & Zhu, C. (2003). Direct observation of catch bonds involving celladhesion molecules. Nature, 423(6936), 190-193. (Pubitemid 36569544)
60. Evans, E., Leung, A., Heinrich, V., & Zhu, C. (2004). Mechanical switching and coupling between two dissociation pathways in a P-selectin adhesion bond. Proceedings of the National Academy of Sciences of the United States of America, 101(31), 11281-11286. (Pubitemid 39038338)
61. Ludwig, R. J., Boehme, B., Podda, M., Henschler, R., Jager, E., Tandi, C., et al. (2004). Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis. Cancer Research, 64(8), 2743-2750. (Pubitemid 38500611)
62. Hejna, M., Raderer, M., & Zielinski, C. C. (1999). Inhibition of metastases by anticoagulants. Journal of the National Cancer Institute, 91(1), 22-36. (Pubitemid 29042440)
63. Akl, E. A., van Doormaal, F. F., Barba, M., Kamath, G., Kim, S. Y., Kuipers, S., et al. (2007). Parenteral anticoagulation for prolonging survival in patients with cancer who have no other indication for anticoagulation. Cochrane Database of Systematic Reviews, 3, CD006652.
64. Lebeau, B., Chastang, C., Brechot, J. M., Capron, F., Dautzenberg, B., Delaisements, C., et al. (1994). Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group. Cancer, 74(1), 38-45. (Pubitemid 24187607)
65. Zacharski, L. R., Henderson, W. G., Rickles, F. R., Forman, W. B., Cornell, C. J., Jr., Forcier, R. J., et al. (1984). Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study #75. Cancer, 53(10), 2046-2052. (Pubitemid 14101772)
66. Ornstein, D. L., & Zacharski, L. R. (2001). Treatment of cancer with anticoagulants: rationale in the treatment of melanoma. International Journal of Hematology, 73(2), 157-161. (Pubitemid 33758855)
67. Ma, Y. Q., & Geng, J. G. (2000). Heparan sulfate-like proteoglycans mediate adhesion of human malignant melanoma a375 cells to P-selectin under flow. Journal of Immunology, 165(1), 558-565. (Pubitemid 30429551)
68. Wei, M., Gao, Y., Tian, M., Li, N., Hao, S., & Zeng, X. (2005). Selectively desulfated heparin inhibits P-selectin-mediated adhesion of human melanoma cells. Cancer Letters, 229(1), 123-126. (Pubitemid 41262548)
69. Hostettler, N., Naggi, A., Torri, G., Ishai-Michaeli, R., Casu, B., Vlodavsky, I., et al. (2007). P-selectin- and heparanase-dependent antimetastatic activity of non-anticoagulant heparins. The FASEB Journal, 21(13), 3562-3572. (Pubitemid 350075146)
70. Schlesinger, M., Simonis, D., Schmitz, P., Fritzsche, J., & Bendas, G. (2009). Binding between heparin and the integrin VLA-4. Thrombosis and Haemostasis, 102(5), 816-822.
71. Niers, T. M., Bruggemann, L. W., Klerk, C. P., Muller, F. J., Buckle, T., Reitsma, P. H., et al. (2009). Differential effects of anticoagulants on tumor development of mouse cancer cell lines b16, k1735 and ct26 in lung. Clinical & Experimental Metastasis, 26(3), 171-178.